References and Notes
- 1
Len C.
Mackenzie G.
Tetrahedron
2006,
62:
9085
-
2a
Len C.
Postel D.
Curr. Org. Synth.
2006,
3:
261
-
2b
Lin TS.
Schinazi RF.
Prusoff WH.
Biochem. Pharmacol.
1987,
36:
2713
-
2c
Balzarini J.
Van Aerschot A.
Herdewijn P.
De Clercq E.
Biochem. Pharmacol.
1989,
38:
869
-
3a
Ouma S.
Kumamoto H.
Kawato M.
Tanaka H.
Tetrahedron
2002,
58:
2497
-
3b
Kumamoto H.
Tanaka H.
J. Org. Chem.
2002,
67:
3541
-
3c
Haraguchi K.
Itoh Y.
Tanaka H.
Miyasaka T.
Tetrahedron
1993,
49:
1371
-
3d
Schmalz HG.
Hebler E.
Bats JW.
Durner G.
Tetrahedron Lett.
1994,
35:
4543
-
3e
Hebler E.
Schmalz HG.
Durner G.
Tetrahedron Lett.
1994,
35:
4547
-
3f
Schlawe D.
Majdalani A.
Velcicky J.
Hebler E.
Wieder T.
Prokop A.
Schmalz HG.
Angew. Chem. Int. Ed.
2004,
43:
1731
-
4a
Ewing DF.
Fahmi NE.
Len C.
Mackenzie G.
Ronco G.
Villa P.
Shaw G.
Nucleosides Nucleotides
1999,
18:
2613
-
4b
Ewing DF.
Fahmi NE.
Len C.
Mackenzie G.
Pranzo A.
J. Chem. Soc., Perkin Trans. 1
2000,
3561
-
4c
Belloli E.
Len C.
Mackenzie G.
Ronco G.
Bonte JP.
Vaccher C.
J. Chromatogr., A
2001,
943:
91
-
4d
Ewing DF.
Len C.
Mackenzie G.
Ronco G.
Villa P.
Tetrahedron: Asymmetry
2000,
11:
4995
-
4e
Selouane A.
Vaccher C.
Villa P.
Postel D.
Len C.
Tetrahedron: Asymmetry
2002,
13:
407
-
4f
Pilard S.
Riboul D.
Glacon V.
Moitessier N.
Chapleur Y.
Postel D.
Len C.
Tetrahedron: Asymmetry
2002,
13:
529
-
4g
Egron D.
Perigaud C.
Gosselin G.
Aubertin AM.
Faraj A.
Selouane A.
Postel D.
Len C.
Bioorg. Med. Chem. Lett.
2003,
13:
4473
-
5a
Nicolaou KC.
Bulger PG.
Sarlah D.
Angew. Chem. Int. Ed.
2005,
44:
4490
-
5b
Trnka TM.
Grubbs RH.
Acc. Chem. Res.
2001,
34:
18
-
6a
Poulsen CS.
Madsen R.
Synthesis
2003,
1
-
6b
Diver ST.
Giessert AJ.
Chem. Rev.
2004,
104:
1317
-
6c
Kinoshita A.
Mori M.
J. Org. Chem.
1996,
61:
8356
-
6d
Mori M.
Adv. Synth. Catal.
2007,
349:
121
-
7a
Poulsen CS.
Madsen R.
J. Org. Chem.
2002,
67:
4441
-
7b
Marco-Contelles J.
Arroyo N.
Ruiz-Caro J.
Synlett
2001,
652
-
7c
Boyer FD.
Hanna I.
Ricard L.
Org. Lett.
2001,
3:
3095
-
7d
Leeuwenburgh MA.
Appeldoorn CCM.
van Hooft PAV.
Overkleeft HS.
van der Marel GA.
van Boom JH.
Eur. J. Org. Chem.
2000,
873
-
7e
Clark JS.
Hamelin O.
Angew. Chem. Int. Ed.
2000,
39:
372
-
7f
Leeuwenburgh MA.
Kulker C.
Duynstee HI.
Overkleeft HS.
van der Marel GA.
van Boom JH.
Tetrahedron
1999,
55:
8253
-
7g
Dohlem F.
Lievre C.
Demailly G.
Eur. J. Org. Chem.
2003,
2336
- 8
Mori M.
Sakakira N.
Kinoshita A.
J. Org. Chem.
1998,
63:
6082
-
9a
Kinoshita A.
Sakakibara N.
Mori M.
J. Am. Chem. Soc.
1997,
119:
12388
-
9b
Kinoshita A.
Sakakibara N.
Mori M.
Tetrahedron
1999,
8155
-
9c
Smulik JA.
Diver ST.
J. Org. Chem.
2000,
65:
1788
-
9d
Mori M.
Tonogaki K.
Nishiguchi N.
J. Org. Chem.
2002,
67:
224
- 10
Lloyd-Jones GC.
Margue RG.
de Vries JG.
Angew. Chem. Int. Ed.
2005,
44:
7442
- 11
Fürstner A.
Langemann K.
J. Am. Chem. Soc.
1997,
119:
9130
-
13a
Hansen EC.
Lee D.
J. Am. Chem. Soc.
2003,
125:
9582
-
13b
Hansen EC.
Lee D.
J. Am. Chem. Soc.
2004,
126:
15074
- 16
Barfield M.
Spear RJ.
Sternhell S.
J. Am. Chem. Soc.
1975,
97:
5160
12
RCEYM Reaction of
rac
-15 and
rac
-16 - Typical Procedure
The ruthenium catalyst 5 (3% mol) was dissolved in CH2Cl2 (26 mL) and ethylene gas was passed through the solution for 20 min. The enyne mixture of rac-15 and rac-16 (400 mg, 0.98 mmol) in CH2Cl2 (12 mL) was then added and the mixture was stirred under ethylene at 20 °C during 5 d. The volatiles were eliminated under reduced pressure and the residue was purified by flash chromatography (5% EtOAc in hexane) to give rac-cis-22 (100 mg, 25%) and rac-trans-22 (100 mg, 25%) in order of fractions eluted.
14 Selected physico-chemical data for compound cis-12: R
f
= 0.50 (5% EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ = 7.71 (m, 4 H, Ph), 7.45 (m, 6 H, Ph), 6.48 (dd, 1 H, J = 12, 18 Hz, =CH), 6.18 (s, 1 H, H3), 5.87 (s, 1 H, H5), 5.46 (d, 1 H, J = 18 Hz, =CH), 5.23 (d, 1 H, J = 12 Hz, =CH), 4.80 (m, 1 H, J = 1 Hz, H2), 3.68 (m, 4 H, OCH
2CH3, CH2OSi), 1.23 (t, 3 H, J = 8 Hz, CH3), 1.06 (s, 9 H, 3 CH3) ppm. 13C NMR (75 MHz, CDCl3): δ = 138.9 (C4), 136.0 (Ph), 135.9 (Ph), 133.9 (C3), 133.8 (Ph), 130.4 (=CH), 128.1 (Ph), 118.0 (=CH2), 107.6 (C5), 85.7 (C2), 67.6 (CH2OSi), 62.6 (OCH2), 27.2 (CH3 of t-Bu), 19.6 (Cq of t-Bu), 15.8 (CH3) ppm. ESI-HRMS: m/z calcd [M + Na+]: 431.2018; found: 431.2034.
15 Selected physico-chemical data for compound trans-12: R
f
= 0.20 (5% MeOH-CH2Cl2). 1H NMR (300 MHz, CDCl3): δ = 7.65 (m, 4 H, Ph), 7.38 (m, 6 H, Ph), 6.43 (m, 1 H, J = 12, 18Hz, =CH), 5.98 (s, 1 H, H3), 5.96 (d, 1 H, J = 4 Hz, H5), 5.43 (d, 1 H, J = 18, =CH), 5.24 (d, 1 H, J = 12 Hz, =CH), 4.90 (m, 1 H, H2), 3.72 (m, 4 H, OCH
2CH3, CH2OSi), 1.26 (t, 3 H, J = 8 Hz, CH3), 1.04 (s, 9 H, 3 CH3) ppm. 13C NMR (75 MHz, CDCl3): δ = 138.8 (C4), 136.0 (Ph), 133.9 (Ph), 130.6 (C3), 130.0 (Ph), 129.0 (=CH), 128.1 (Ph), 118.0 (=CH2), 107.6 (C5), 85.6 (C2), 66.6 (CH2OSi), 62.1 (OCH2), 27.2 (CH3 of t-Bu), 19.6 (Cq of t-Bu), 15.8 (CH3). ESI-HRMS: m/z calcd [M + Na+]: 431.2018; found: 431.2025.